[New developments in therapeutics for infectious diseases].
Yamaguchi
Keizo
K
D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D017209:Apoptosis; D016207:Cytokines; D004195:Disease Models, Animal; D005699:Galactosylceramides / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular; D007694:Killer Cells, Natural / Q000276:immunology; D007877:Legionnaires' Disease / Q000209:etiology / Q000628:therapy*; D018942:Macrolides / Q000008:administration & dosage; D011018:Pneumonia, Pneumococcal / Q000209:etiology / Q000628:therapy*; D011552:Pseudomonas Infections / Q000209:etiology / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity; D053038:Quorum Sensing; D018417:Th1 Cells / Q000276:immunology; D014612:Vaccines
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D016207:Cytokines; D005699:Galactosylceramides; D018942:Macrolides; D014612:Vaccines; C493154:alpha-galactosylceramide; C088386:homoserine lactone; D015107:4-Butyrolactone